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1

However, current monitoring techniques discourage regu
NON - INVASIVE OPTICAL BLOOD GLUCOSE
lar use due to the inconvenient and painful nature of drawing
DETECTION UTILIZING SPECTRAL DATA
blood through the skin prior to analysis, which causes many
ANALYSIS
diabetics to not be as diligent as they should be for good
5 blood glucose control. As a result , non - invasive measure
CROSS - REFERENCE TO RELATED
ment of glucose concentration is a desirable and beneficial
APPLICATION
development for the management of diabetes. A non - inva
sive monitor will make testing multiple times each day
This application is a continuation patent application of pain
- free and more palatable for children with diabetes .
co -pending U.S. patent application Ser. No. 15 /464,253 , 10 According
to a study published in 2005 (J. Wagner, C.
filed Mar. 20 , 2017 , and entitled METHOD AND SYSTEM Malchoff, and
G. Abbott, Diabetes Technology & Therapeu
FOR NON - INVASIVE OPTICAL BLOOD GLUCOSE tics , 7 (4 ) 2005 , 612-619 ) , people with diabetes would per
DETECTION UTILIZING SPECTRAL DATA ANALYSIS ,
SMBG more frequently and have improved quality of
which is a continuation patent application of U.S. patent form
life
with
non - invasive blood glucose monitoring device .
application Ser. No. 13 / 610,423 , filed Sep. 11 , 2012 , issued 15 There aexist
a number of non - invasive approaches for
as U.S. Pat . No. 9,629,576 and entitled METHOD AND
METHOD AND SYSTEM FOR

blood glucose determination . One technique of non -invasive
blood chemical detection involves collecting and analyzing
light spectra data .

SYSTEM FOR NON - INVASIVE OPTICAL BLOOD GLU
COSE DETECTION UTILIZING SPECTRAL DATA

ANALYSIS , which is a divisional of prior U.S. patent

application Ser. No. 12/ 425,535 , filed Apr. 17 , 2009 , issued 20 Extracting information about blood characteristics, such
as U.S. Pat. No. 8,340,738 , which are all hereby incorpo- as glucose concentration from spectral or other data obtained
rated herein by reference in their entirety, and also claims from spectroscopy, is a complex problem due to the presence
priority to U.S. Provisional Patent Application Ser. No. of components .g ., skin , fat, muscle, bone, interstitial
61 /055,303 , filed on May 22 , 2008 , the disclosure of which fluid ) other than blood in the area that is being sensed . Such
is incorporated herein by reference, and also claims priority 25 other components can influence these signals in such a way
to U.S. Provisional Patent Application Ser. No. 61 /089,152 , as to alter the reading. In particular, the resulting signal may
filed on Aug. 15 , 2008 , the disclosure of which is incorpo- be much larger in magnitude than the portion of the signal

that corresponds to blood , and therefore limits the ability to

rated herein by reference .

BACKGROUND OF THE INVENTION

30

accurately extract blood characteristics information.
The present invention is directed to overcoming one or
more of the problems set forth above .

Diabetes is a chronic disease that, when not controlled,
SUMMARY OF INVENTION
over time leads to serious damage to many of the body's
systems , including the nerves, blood vessels , eyes , kidneys
and heart. The National institute of Diabetes and Digestive 35 In an aspect of the present invention, a method for
and Kidney Diseases (NIDDK) estimates that 23.6 million detecting glucose in a biological sample is disclosed . The
people , or 7.8 percent of the population in the United States, method includes utilizing at least one light source configured
had diabetes in 2007. Globally, the World Health Organiza- to strike a target area of a sample, utilizing at least one light
tion (WHO ) estimates that more than 180 million people detector positioned to receive light from the at least one light
have diabetes , a number they expect to increase to 366 40 source and to generate an output signal, having a time
million by 2030 , with 30.3 million in the United States . dependent current, which is indicative of the power of light
According to the WHO , an estimated 1.1 million people died detected , receiving the output signal from the at least one
from diabetes in 2005. They project that diabetes deaths will light detector with a processor and based on the received

increase by more than 50% between 2006 and 2015 overall output signal, calculating the attenuance attributable to
and by more than 80 % in upper -middle income countries. 45 blood in a sample present in the target area with a ratio factor
The economic burden from diabetes for individuals and

society as a whole is substantial. According to the American
Diabetes Association , the total annual economic cost of
diabetes was estimated to be $ 174 billion in the United
States in 2007. This is an increase of $ 42 billion since 2002. 50

with the processor, eliminating effect of uncertainty caused

by temperature dependent detector response of the at least
one light detector with the processor, and determining a
blood glucose level associated with a sample present in the
target area with the processor based on the calculated
This 32 % increase means the dollar amount has risen over attenuance with the processor.
$ 8 billion more each year.
In yet another aspect of the present invention , a system for
A vital element of diabetes management is the self- detecting glucose in a biological sample is disclosed . This
monitoring of blood glucose ( SMBG) concentration by system includes at least one light source configured to strike
diabetics in the home environment. By testing blood glucose 55 a target area of a sample, at least one light detector posi
levels often , diabetics can better manage medication , diet , tioned to receive light from the at least one light source and
and exercise to maintain control and prevent the long - term to generate an output signal, having a time dependent
negative health outcomes . In fact, the Diabetes Control and current, which is indicative of the power of light detected, a
Complications Trial (DCCT ) , which followed 1,441 diabet- processor configured to receive the output signal from the at
ics for several years , showed that those following an inten- 60 least one light detector based on the received output signal ,
sive - control program with multiple blood sugar tests each calculate the attenuance attributable to blood in a sample
day, as compared with the standard - treatment group , had present in the target area with a ratio factor, eliminate effect
only one - fourth as many people develop diabetic eye dis- of uncertainty caused by temperature dependent detector
ease , half as many develop kidney disease , one - third as response of the at least one light detector, and then determine
many develop nerve disease , and far fewer people who 65 a blood glucose level associated with a sample present in the
already had early forms of these three complications got target area based on the calculated attenuance with the
worse .

processor.
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These are merely some of the innumerable aspects of the
present invention and should not be deemed an all- inclusive
listing of the innumerable aspects associated with the pres

maximum or peak reading 104 and minimum or valley
reading 106. The peak reading 104 of the plot corresponds

ent invention .

BRIEF DESCRIPTION OF THE DRAWINGS

For a better understanding of the present invention , reference may be made to accompanying drawings, in which :
FIG . 1 illustrates a plot of a pulse wave corresponding to
light absorption of arterial blood , according to exemplary
embodiments ;
FIG . 2 illustrates an exemplary system for obtaining
spectral data ;
FIG . 3 illustrates a plot of A (t) , calculated according to
Equation ( 9 ) using data in FIG . 1 ; and
FIG . 4 is a basic illustrative schematic of a preamplifier
circuit that converts photocurrent into voltage prior to digitization .

DETAILED DESCRIPTION OF THE
INVENTION

In the following detailed description, numerous exem

plary specific details are set forth in order to provide a
thorough understanding of the invention . However, it will be
understood by those skilled in the art that the present
invention may be practiced without these specific details, or
with various modifications of the details. In other instances,
well known methods, procedures, and components have not
been described in detail so as not to obscure the present
invention .
Optical spectroscopy can be used to determine the amount
of light absorbed and scattered , i.e. , attenuated , by a bio
logical sample such as a human finger. By measuring the
amount of light absorbed by the sample, it is possible to
determine glucose , cholesterol, and hemoglobin levels of a
subject non - invasively. Fingertip measurements are usually
preferred because of the large concentration of capillaries in
the fingertip and because of the conversion of arterial blood
into venous blood that occurs in the fingertip. However, the
techniques of the present invention are not limited to use
with a fingertip . For example, the biological sample could be
a human earlobe .
When light is transmitted through a biological sample,
such as a human finger, the light is attenuated by various
components of the finger including skin , muscle, bone , fat,
interstitial fluid and blood . It has been observed , however,
that light attenuation by a human finger exhibits a small
cyclic pattern that corresponds to a heartbeat. It is believed
that this cyclic pattern will be present in measurements of
many other human body parts, the earlobe being one of
many examples.
FIG . 1 depicts a plot 102 of a detector photocurrent, ID (t ),
that corresponds to the power of light received by a detector
after the light has passed through a subject's finger. As can
be seen, the detector photocurrent exhibits a cyclic pattern .
This cyclic pattern is due to the subject's heartbeat, which
cyclically increases and decreases the quantity of blood in
the subject's capillaries ( or other structures ). Although the
magnitude of the cyclic pattern is small in comparison to the
total photocurrent generated by the detector, considerable
information can be extracted from the cyclic pattern of the
plot 102. For example, assuming that the person's heart rate
is sixty beats per minute , the time between the start of any
pulse beat and the end of that pulse beat is one second .
During this one - second period, the photocurrent will have a

to when there is a minimum amount of blood in the

capillaries, and the valley reading 106 corresponds to when

5 there is a maximum amount of blood in the capillaries . By
using information provided by the peak and valley of the
cyclic plot , the optical absorption and scattering by major
finger constituents that are not in the capillaries, such as
skin , fat, bones, muscle and interstitial fluids, are excluded .
10 excluded
These major
constituents that are not in the capillaries are
because they are not likely to change during the
time interval of one heartbeat. In other words, the light that
is absorbed and scattered, i.e. , attenuated, by the blood can
be detected based on the peaks and valleys of the plot 102 .
15 Assuming that the peak of the cyclic photocurrent gen
erated by the light-sensing device is Ip , the adjacent valley
of the cyclic photocurrent is Iv, and the photocurrent gen
erated by the light-sensing device without a human finger is
Io , the transmittances corresponding to the peak and valley

20 photocurrents can be defined as :

25

30

Ty --Toly? and

(1 )

lp

(2)

Tp =

To

The corresponding peak and valley absorbance are :
Apo - log (Tv)

(3)

and

35

Ap = -log ( Tp)

(4)

The difference between Ay and Ap represents the light
absorption and scattering by the blood in the finger, exclud
ing non- blood constituents:
40
AA = Ay - Ap = log1

45

(5)

As can be seen in the algorithm shown in Equation ( 5 ) ,
AA does not depend on 1o . Thus, calculating AA does not
require a determination of the current generated by the
light- sensing device without a sample . Monitoring the pho

tocurrent corresponding to light power transmitted through
50 a sample is sufficient to calculate AA .

FIG . 2 depicts a simplified block diagram of an exemplary
apparatus for use in an exemplary embodiment. Optical
measurement system , which is generally indicated by
numeral 200 , uses the " pulsatile” concept for determining an
55 amount of light absorbed and scattered solely by the blood
in a sample (a human finger in this exemplary embodiment).
A power source 201 , such as a battery, provides power to a
light source 202 that generates a plurality of light beams
204 , 206 , 208 , 210 that are directed toward the top of the
60 finger of a subject. In an exemplary embodiment, each of the
light beams 204 , 206 , 208 , 210 have the same wavelength or
a different wavelength range , typically within 800 nm to
1600 nm . Although the optical measurement system 200 is
described herein as generating four (4 ) light beams , it is
65 contemplated that the light source 202 can be altered to
generate fewer light beams or additional light beams in other
embodiments.
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A first aperture 212 ensures that the light beams 204 , 206 , that the rate of heartbeat is in the order of one per second .
208 , 210 strike a target area of the finger. A second aperture For example, 25 seconds would be needed for increasing the
214 ensures that the portion of the light beams that are S / N ratio by a factor of five, and 100 seconds would be
transmitted through the finger strike a lens 216. Light beams needed for increasing the S /N ratio by a factor often . In
204 , 206 , 208 , 210 are attenuated by the finger and compo- 5 comparison, current commercial blood drawing glucose
nents of the optical measurement system 200 , and , thus, meters can determine blood glucose level within 5 seconds .
detection time will significantly increase
attenuated light beams 218 , 220 , 222 , 224 are emitted from Furthermore , long
errors due to finger movement, light power
the finger. The attenuated light beams 218 , 220 , 222 , 224 measurement
, device temperature change, etc. Thus, there is a need
strike the lens 216 , and the lens 216 collects the attenuated drift
for new techniques to measure blood glucose levels quickly
light beams 218 , 220 , 222 , 224 so that they impinge more 10 and
accurately.
efficiently on a detector block 226 .
Improving
S /N Ratio by Standard Deviation
The detector block 226 is positioned directly under the
The
time
detector photocurrent output, Io (t ),
lens 216 and comprises a plurality of tight-sensing devices shown in FIGdependent
. 1 can be expressed as the sum of a small time
( LSD ) 228, 230, 232, 234 such as an array of photodiodes. 15 dependent cyclic photocurrent Af(t), corresponding to the
According to one aspect of the optical measurement system heartbeat, a noise current n (t) , and a constant baseline
200 , each of the light-sensing devices 228 , 230 , 232 , 234 photocurrent Igi
detects a specific wavelength of light as defined by corre
(7)
1o ( t ) = 13 + Al ( t) + n ( t)
sponding interference filters ( IF ) 236 , 238 , 240 , 242 , respec
tively. The interference filter transmits one or more spectral 20 The above Equation can be re - arranged as :
bands or lines of light, and blocks others .
Each of the light - sensing devices 228 , 230 , 232 , 234
(8)
10 (1) = 1+ Al( t) + n ( t)
generates a corresponding photocurrent signal that is pro
??
??
portional to the power of the light received by the particular
light sensing device. The photocurrent signal generated by 25
the photodiode can be converted to another form of signal,
common logarithm to both side of the Equation
such as an analog voltage signal or a digital signal. A (8)Applying
, one obtains :

processor 243 is coupled to the detector block 226 and is

configured to calculate the change of photocurrent signals
According to one aspect , the processor 243 executes an
algorithm such as shown in the Equation ( 5 ) to calculate the

244 , 246 , 248 , 250 .

30

(9 )

18

change in the light absorption ( AA) solely caused by the

blood in the finger. Thereafter, this quantitative calculation
of light absorption of the blood can be used to determine a

Id (t)

A(0)= loe/'1001= left + Al(t) + n ( t)

35

FIG . 3 , which is generally indicated by numeral 300 ,
shows a typical A (t) plot 302 , calculated according to

characteristic of the blood . For example, by comparing the Equation ( 9 ) using data in FIG . 1. For a pulse function Aft)
calculated light absorption value to predetermined values shown in FIG . 3 , the following key relationship exists during
corresponding to different glucose levels stored in a memory the time interval of one heartbeat:
0 [ A ( 1 ) ] = kAA
( 10 )
( not shown ), a blood - glucose level of the subject can be
determined
40
in
which
o
[
A
(
t
)
]
is
the
Standard
Deviation
of
A
(
i
)
,
and
k
is
A difficulty associated with the finger based pulsatile a proportional constant.
detection methodology is low signal -to -noise ( S / N ) ratio ,
the fact that Ig is a constant and o ( log 1x ) = 0 ,
because the amplitude of cyclic pattern ( i.e. , the difference oneConsidering
obtains:
between peak and valley) is typically 1 % -2 % of the total
( 12)
Q [ A (0) ] = o [ log ID ( 0) ]
photocurrent generated by the light power transmitted 45

through the finger. To obtain a S/N ratio of 100 : 1 in the
determination of AA , the baseline noise of the device being
used to measure the light absorption by the finger should not
be larger than 3.0x10- in absorbance (peak to peak ), within
a 10 Hz bandwidth .
However, a 3.0x10-5 absorbance ( peak to peak ) baseline
noise level within a 10 Hz bandwidth is difficult to obtain
with the low light power levels that are used by some
battery -powered hand held non - invasive blood chemical

Therefore, the peak - to -valley height of the A?t) plot
during the time interval of one heartbeat can be obtained
directly from the standard deviation of the logarithm of
Id ( t):

50

?? =

0 [ A (1)] o?log Ip ( ) ]
k

( 13 )

k

measurement
devices. One solution involves data averaging. 55 A major advantage of Equation ( 13 ) is that high S / N ratio
To increase the S / N ratio , the averaged value of AA , as
defined by the Equation below, is used in further calculation

to extract blood glucose concentration :

?? = ???
;
j= 1

( 6)

can be achieved within short data acquisition time (approxi
mately one second) , as explained below.

In a finger based pulsatile measurement depicted by FIG .
2 , the value of the sum , Al (t ) + n (t) is typically less than 2 %
60 of the large constant baseline photoeurrent 1b . Therefore,

In Equation ( 6 ) , M is the number of heartbeats during the 65
time interval of the pulsatile measurement. However, this
approach requires long data acquisition time , due to the fact

Equation ( 9 ) can be approximated as :

A(n)= 100 101

1 Al( t) + n ( t)
In 10

??

( 14 )
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Similarly , the standard deviation of A (t) can be approxi

mated as :

?? (?; )

Qi ( C , 7) =

( 17)

? ( C, ? ;, T)

N

? ?C , ? , ? )
? ?? (?; ) Šec

i= 1

1
o [ A (1 )] = In 10 Vo2[Al(t)??] +02 [n ( 1)]

( 15 ) 5

in which N is total number of wavelength employed . Pref

erably, N typically ranges from twenty to thirty.
Equation ( 15 ) demonstrates great noise reduction power
Based on Equations ( 13 ) and ( 17 ) , Q (CT) is linked to the
of Equation ( 13 ) . For example, for a relatively high baseline 10 detector photocurrent at each wavelength l? , ID (ài t) , by the
noise with the ratio
following Equation :
p=

[ n ( t) ]
o [log Al ( t) ] = 0.1 ( or 10 % ) ,

15

Q: ( C, T) =

?? ( ?; )

o [log ID ( ;, 1 ) ] / k
N

N

? ?? ( ? ;)) i = 1 o?log / ( , 1 ) ] / k
i= 1

o [logId (ii, 1) ]
o [ logId ( ;, ) ]
i= 1

( 18 )

N

the contribution to o [ A ( t )] from the baseline noise n(t) is

estimated to be less than 0.005 (or 0.5 % ), corresponding to
detection time . As such , dramatic noise reduction can be 20
obtained without increasing the data acquisition time , and a
finger based pulsatile measurement can be completed within
the time interval of one heartbeat (which is approximately
one second) , and the requirement for the S / N ratio of 100 to 25
1 in determination of AA can be satisfied using an optical
system with a baseline noise of about 6.0x10-4 absorbance
(peak to peak) within a 10 Hz bandwidth . It should be
pointed out that when the baseline noise of an optical system
is dominated by shot noise due to low light illumination
power, a noise reduction by a factor of 20 equals an 30
increasing in light illumination power by a factor of
202 = 400 .
This ability of obtaining higher S / N ratio within the very
short data acquisition time , e.g. , less than one second, will
significantly reduce detection error caused by factors such as 35
finger movement, temperature change, and light powerdrift
during the measurement, and therefore dramatically improve
the accuracy and reproducibility of the pulsatile detection
methodology
Furthermore , the value of k does not change with wave- 40
length , because transmitted lights at all wavelengths have
identical pulse shape due to the heartbeat. As a result, the
constant k will be cancelled in data normalization discussed
in next section, and o [ log ID ( t )] will be used in further
regression analysis to establish correlation between the 45
optical measurement and blood glucose level . This will
greatly simplify the data analysis process since o [ log ID ( t)]

an increase in S / N ratio by a factor of 20 without increasing

involves only two standard math functions available in most

popular spreadsheet programs such as Microsoft EXCEL® .
EXCEL® is a federally registered trademark of Microsoft 50

As shown by Equation ( 18 ) , the constant k is cancelled

and o [ log ID (t)] will be used in further regression analysis to
establish correlation between the optical measurement and
blood glucose level . This is possible because data are taken
simultaneously from all detection channels.
A correlation between optical measurement and blood
glucose concentration can be established according to the
following Equation :
N

Coptical = a (:(T)Q;(C, 7)

( 19)

i= 1

in which Copticai is the blood glucose concentration predicted

by the optical measurement, Q ( C , T ) is defined by Equations
( 17 ) and ( 18 ) , and a ( T) is the temperature dependent regres
sion coefficient corresponding to wavelength ;. The values
of a ( T ) can be extracted using proper statistics methods such
as Partial Least Squares ( PLS ) regression .
Equation ( 19 ) represents ideal cases when large number
of calibrations can be made at different finger temperatures.
In reality, frequently only a limited number of calibrations
can be made ( e.g. , 15 to 20 ) , and each may be taken at a
different finger temperature . Under this condition , the finger
temperature can be treated as an independent variable , and

the above Equation can be approximated as :

- Max

Copricat = b ;Q:(C, T) + nT

(20)

i= 1

Corporation, having a place of business at One Microsoft
in which b ; is the temperature independent regression coef
Way, Redmond, Wash . 98052-6399 .
Normalization
ficient corresponding to wavelength d? , and n is the regres
At each wavelength , the absorption AA ( ) is linked to sion coefficient for the finger temperature. The values of b ;
the increase of amount of blood ( AB ) in the optical sensing 55 and that of n can be extracted using proper statistics methods
area of the fingertip due to the heartbeat by the following such as Partial Least Squares ( PLS ) regression.
Equation :
Ratio Methodology
( 16)
Alternatively , the uncertainty from the variable AB can be
AA ( ;) = E ( C ,2,7 ) AB
cancelled
by introducing a ratio factor Y ; at wavelength ::
in which & (C , 1i , T) is the absorption /scattering coefficient of 60
blood at wavelength , finger temperature T , and blood
glucose concentration C. It is well understood that the
?? (?; ) E ( C , 1;, T) o [log /di , 1 )]
( 21 )
Y ; (C , T) = ??( ? ; ) ??C , ? ;, T ) o [log/p (1 ;, t)]'
variable AB differs from person to person , and may even
change from day to day for the same person .
The uncertainty from the variable AB can be cancelled by 65
introducing the normalization factor Q : (CT) at each wave- in which j can be any number from 1 to N , assuming that the
length N? , as defined by the Equation below :
device collects signal at all N wavelengths.
=
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Similar to the normalization algorithm discussed before ,
a correlation between optical measurement and blood glucose level can be established according to the following

the very short data acquisition time interval of approxi
mately one second , one obtains :
o [log 100 ,, t) ] = o [log P (1,1 ) ]

Equation:

(26)

As such , the uncertainty caused by detector temperature
Tdi( t) is eliminated by the use of this standard deviation
methodology
( 22)
Voltage Detection Mode
Copticat = f (T ) Y ; ( C, T)
In the device configuration shown in FIG . 2 , the photo
10 current of ith photodiode detector Ibig t) is typically
into a voltage using a preamplifier before digiti
in which Coptical is the blood glucose concentration predicted converted
zation
.
FIG
. 4 shows the schematic circuit diagram of a
by
the opticalmeasurement, Y,(C , T) is defined by Equation typical preamplifier
, which is generally indicated by numeral
( 21 ) , and f ( T ) is the temperature dependent regression 400
.
coefficient corresponding to wavelength à;. The value of
The output voltage 412 of ith preamplifier 400 , in cou
f ; ( T ) can be obtained using statistics methods such as Partial 15 pling
with ith photodiode detector 408 , can be expressed as :
Least Squares ( PLS ) regression .
5

Equation (22) represents ideal cases when large number

V :(t) = R ,ID (9,1 )= R0;[1 + X :( TR:(1)-25 ° C . ) ]

,7)

(27)

of calibration can be made at different finger temperatures .
In the above Equation (27 ) , Roi is the resistance value of
In reality , frequently only limited number of calibration can feedback
resistor 402 for ith preamplifier at 25 ° C. , Xi is the
be made (e.g. , 15 to 20) , and each may be taken at a different 20 temperature
of the resistor, and Tri?t) is the
finger temperature . Under this condition , the finger tempera temperature ofcoefficient
the
resistor
Applying common logarithm to
ture can be treated as an independent variable, and the above both side of the Equation .(27
) , one obtains :
Equation can be approximated as :
log Vi( t ) = log Rio + log [1 + X : (Tri (t ) -25 ° C . ) ] + log

25
N

Coptical = h;Y; (C, T) + BT

( 23 )

in which h ; is the temperature independent regression coef
ficient corresponding to wavelength ài , and ß is the regres
sion coefficient for the finger temperature. The values of h;
and that of ß can be extracted using proper statistics methods
such as Partial Least Squares ( PLS ) regression.
Elimination of the Effect of Temperature Dependent Device
Response
It is well understood that the detector sensitivity of a
silicon photodiode detector is a function of wavelength and
temperature. For the device configuration shown in FIG . 2 ,
which is generally indicated by numeral 200 , the light power
received by ith silicon diode detector, corresponding to
wavelength hi , is converted into a photocurrent according to
the following Equation :
Id ( it ) = P ( ) ; t) S ( ) [ 1 + y ( ;) (TDi( t) -25 ° C. ) ]

IN; )

( 28 )

Considering the fact that Roi is a constant and that the
resistor temperature Tri( t) does not change during the very
short data acquisition time interval of approximately one
30

second, one obtains:

o [log V :(0) ] = o [ log ID ( 7. ,t )]

( 29 )

Substituting Equation (26 ) into Equation ( 29 ) , one
35

obtains :
o [log V ; ( ) ] = o [ log P ( VT ) ]

( 30 )

As such , the uncertainty caused by resistor temperature Tr (t)
is eliminated .

Under the voltage detection mode , the normalization
factor in Equation ( 18 ) can be expressed as :
40

Q : ( C , T) =

N

o [logV ;( 0)]
o [logV;( )]

(31 )

( 24 ) 45

In the above Equation ( 24 ) , Pai , t ) is the light power
received by the detector , S. ( ) is the photosensitivity of the
detector at wavelength à ; and 25 ° C. , y ( a ) is the temperature

The mathematic correlation between optical measurement
and blood glucose concentration can then be established
according to Equation ( 19 ) or Equation (20 ) , under corre

in a handheld device used by a person with diabetes under

The mathematic correlation between optical measurement

coefficient of the photosensitivity at wavelength dy, and sponding calibration conditions .
Tdi (t) is the temperature of ith photodiode detector. The 50 Similarly, the ratio factor defined by Equation (21 ) can be
temperature coefficient y(a ;) varies with the wavelength . For expressed as :
example , for Hamamatsu S1337 series photodiode detectors,
Y (ar ) ranges from near zero at 900 nm to over 1.0%/ ° C. at
q [ logV ; (0 )]
1100 nm . This imposes a potential problem for the device
( 32)
Y ;; (C , T) = o [logV ;( r)]
configuration show in FIG . 2 , because it is very difficult to 55
keep temperature of each individual diode detector constant
a normal household /office environment.

uncertainty due to the detector temperature Tdi( t) and blood glucose concentration can then be established
canThis
be eliminated
using the algorithm shown by Equations 60 according calibration
to Equationconditions
(22) or Equation
(23 ) , under corre
. The schematic circuit dia
( 12 ) and ( 13 ) . Applying common logarithm on both sides of sponding
gram of a typical preamplifier 400 also includes a feedback
the Equation (24 ) , one obtains :
log ID ( hi,t ) = log P (),1 ) + log S. ( ;)+ log[ 1 + y () ;)( TDi
( t ) -25 ° C. ) ]

capacitor 404 , an operational amplifier 406 , and a ground

(25 )

Considering the fact that Soa ;) is a constant and that
detector temperature TDi ( t) remains almost constant during

connection 410 .

65 Digitization
The voltage output 412 from the preamplifier 400 is

usually digitized using an analog - to - digital convertor
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(ADC ) . The digitized signal is then sent to a computer for
data analysis. The output of ith ADC , in communication with
ith preamplifier that is in coupling with ith photodiode 408
collecting light power at wavelength , can be expressed by
the following Equation :

( ADC );= (ADC)o + G {[10 ( t)+ IDark ,j]R ,+ A0;}

occur to those skilled in the art . The terms “ have ,” “ having, "
“ includes , ” “ including ,” and similar terms as used in the
foregoing specification are used in the sense of “ optional ” or
“ may include ” and not as “ required .” Many changes, modi
5 fications , variations and other uses and applications of the
present construction will , however, become apparent to

(33 )

those skilled in the art after considering the specification and

the accompanying drawings. All such changes, modifica
In the above Equation (33 ) , (ADC ) oi is the offset of ith tions
, variations and other uses and applications, which do
ADC , G; is the nominal ADC Gain used during the detection , not depart
the spirit and scope of the invention , are
Id ( i , t ) is the photocurrent of ith photodiode detector, i Dark.i 10 deemed to befrom
covered
by the invention, which is limited only
is the dark current of ith photodiode detector, R = R0 [ 1 + % by the claims that follow
. It should be understood that the
( Tri (t )-25 ° C. ) ] ] is the resistance of feedback resistor of ith embodiments disclosed herein
include any and all combi
preamplifier, and Aoi is the offset of ith preamplifier.
nations
of
features
described
in
any
of the dependent claims .
The contribution of the three factors , (ADC )oi, IDarkzi, and
The invention claimed is :
Aoi can be removed by carrying out a dark measurement 15 1. A system for detecting glucose in a biological sample ,
with the light source turned off right before or after the comprising:
corresponding finger measurement. When the light source is
at least one light source configured to generate one or
turned off, the above Equation (33 ) becomes :
more light beams to strike a target area of a sample ;
(34) 20 at least one photocurrent signal generating light detector
(ADC )Dark,I= (ADC )0:+ G ;(I Dark, R :+40 )
positioned to receive light from the at least one light
The difference between the two above Equations (33 ) and
source and to generate an output photocurrent signal ,
( 34 ) reflects ADC output corresponding to the photocurrent:
having a time dependent current, which is indicative of
(35 )
the power of light detected , wherein the at least one
A (ADC) = (ADC) - (ADC )Dark,i = G ;Id ( it)R ;
photocurrent signal generating light detector includes a
Applying common logarithm to both side of the Equation 25
preamplifier having a feedback resistor; and
( 35 ) , one obtains :
a light absorbance change determining algorithm imple
(36 )
log A (ADC ) = log G + log 10 () ;t)+ log R ;
mented processor programmed to calculate a change in
a light absorption caused by blood in the biological
G; and Ri can be considered as constants as long as the
sample and configured to receive the output photocur
time interval between the finger measurement and the dark 30
rent signal from the at least one photocurrent signal
measurement is short. As such , one obtains :
generating light detector and based on the received
(37 )
o [ log A (ADC ) : ] = o [ log ID (77)]
output photocurrent signal to calculate the attenuance
attributable to blood in a sample present in the target
Substituting Equation ( 26 ) into Equation ( 37 ) , one further
area with either a normalization factor or a ratio factor,
obtains :
35
eliminate effect of uncertainty caused by temperature
(38)
o [ log A (ADC ) ; ] = o [ log P (),t ) ]
dependent detector response of the at least one photo
Based on Equation ( 37 ) , the normalization factor defined
current signal generating light detector by calculating a
standard deviation of a logarithm of the time dependent
by Equation ( 18 ) can be expressed as :
output
current generated by the light power from the
40
same target area of the biological sample, and based on
the calculated attenuance, determine a blood glucose
( 39 )
Q : ( C, T) = No [logA (ADC );]
level associated with a sample present in the target area ;
o [logA (ADC ) ;]
an analog - to -digital converter having a digitized volt
age output, wherein the light absorbance change deter
45
mining algorithm implemented processor is configured
The mathematic correlation between optical measurement
to calculate the normalization factor Q :(CT) based on
and blood glucose concentration can then be established
an analog - to - digital converter voltage output A (ADC ) i
according to Equation ( 19 ) or ( 20) , under corresponding
of an ith analog -to -digital converter, where o is a
calibration conditions.
standard deviation according to the equation :
Similar to normalization , the ratio factor defined by 50
Equation ( 21 ) can be expressed as :
logA ( ADC );]
Y ; ( C , T ) = oo [[logA
(ADC ) ;]

(40 )

Q : ( C , T) = N o [logA ( ADC);]
o?logA (ADC );]
55

The correlation between optical measurement and blood
glucose concentration can then be established according to

or a ratio factor Y, (C , T ) based on the analog -to - digital

converter voltage output A (ADC ) ; of the ith analog - to - digital
converter and an analog - to - digital converter voltage output
Equations
(
22
)
or
(
23
)
,
under
corresponding
calibration
60
A (ADC ); of a jih analog -to - digital converter , where o is a
conditions .
standard deviation according to the equation :
Thus, there has been shown and described several

embodiments of a novel invention . As is evident from the

foregoing description, certain aspects of the present inven
tion are not limited by the particular details of the examples 65
illustrated herein , and it is therefore contemplated that other
modifications and applications , or equivalents thereof, will

Yi; ( C , T ) =

o [ logA (ADC );]

o [logA (ADC);
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wherein T is a temperature of the biological sample and
C is a concentration of blood glucose in the biological
sample.
2. A system for detecting glucose in a biological sample ,
wherein the system comprises a processor configured to 5
determine a change in a light absorption caused by blood in
the biological sample, determine an attenuance attributable
to blood in a sample present in a target area with either a
normalization factor or a ratio factor, eliminate effect of
uncertainty caused by temperature dependent detector 10
response of a photocurrent signal generating light detector
by calculating a standard deviation of a logarithm of a time
dependent output current, and determine a blood glucose
level associated with the sample present in the target area
based on the determined attenuance .

15

3. The system of claim 2 , further comprising a light beam
generator configured to generate a light beam to strike the
target area of the sample.

4. The system of claim 3 , wherein the light detector is

positioned to receive light from the light beam generator. 20
5. The system of claim 4 , wherein the light detector
comprises a photocurrent signal generating component con
figured to generate an output photocurrent signal, having a
time dependent current, which is indicative of a power of
light detected.
6. The system of claim 4 , wherein the light detector
comprises a preamplifier containing a feedback resistor.
7. The system of claim 2 , wherein the device is configured

25

a light absorption caused by blood in the biological
sample and configured to receive the output photocur
rent signal from the at least one photocurrent signal
generating light detector and based on the received
output photocurrent signal to calculate the attenuance
attributable to blood in a sample present in the target
area with either a normalization factor or a ratio factor,
eliminate effect of uncertainty caused by temperature
dependent detector response of the at least one photo
current signal generating light detector by calculating a
standard deviation of a logarithm of the time dependent
output current generated by the light power from the
same target area of the biological sample, and based on
the calculated attenuance, determine a blood glucose
level associated with a sample present in the target area ,
wherein the light absorbance change determining algo
rithm implemented processor is configured to calculate
the normalization factor Q : ( C , T ) based on a preampli

fier output voltage Vi (t) of an ith preamplifier as a

function of time , where a is a standard deviation

according to the equation :
Q: ( C, T ) =

o [ logV ; ( 0)]
N

o?logV ; (0)]

to receive the photocurrent signal from the light detector. or a ratio factor Y , ( C , T) based on the preamplifier output
8. The system of claim 2 , wherein the device is configured 30 voltage V (t) of the ish preamplifier and a preamplifier output
to calculate the normalization factor Q : (CT) based on a voltage V (t) of a jih preamplifier as a function of time , where
preamplifier output voltage V (t) of an ith preamplifier as a o is a standard deviation according to the equation:

function of time , where o is a standard deviation according
to the equation:

35

Qi ( C, T) =

o [logV ;( 0)]

Yi; (C , T) = o [ logV ; (t) ]'

o [ logV ; (0)]
o [logV ;(D) ]
i= 1
N

wherein T is a temperature of the biological sample and C
40 is a concentration of blood glucose in the biological sample .
11. A system for detecting glucose in a biological sample ,
or a ratio factor Y. (C , T ) based on the preamplifier output wherein the system comprises a processor configured to
voltage V (t) of an i preamplifier and a preamplifier voltage determine a change in a light absorption caused by blood in
Vj( t) of a jih preamplifier as a function of time, where o is the biological sample , determine an attenuance attributable
a standard deviation according to the equation :
45 to blood in a sample present in a target area with either a
normalization factor or a ratio factor, eliminate effect of
uncertainty caused by temperature dependent detector
o [ logV; ( 1) ]
response of a photocurrent signal generating light detector
Yi; ( C , T ) = o [logV ; (r)]
by calculating a standard deviation of a logarithm of a time
50 dependent output current, and determine a blood glucose
level associated with the sample present in the target area
wherein T is a temperature of the biological sample and C based
on the determined attenuance , wherein the device is
is a concentration of blood glucose in the biological sample. configured
the normalization factor Q : (CT)
9. The system of claim 2 , further comprising an analog based on anto calculate
analog
to
digital converter voltage output
to - digital converter having a digitized voltage output.
(ADC ); of an ith analog -to -digital converter, where a is a
10. A system for detecting glucose in a biological sample, 55 Astandard
deviation according to the equation :
comprising:
at least one light source configured to generate one or
more light beams to strike a target area of a sample;
at least one photocurrent signal generating light detector
positioned to receive light from the at least one light 60
source and to generate an output photocurrent signal ,
having a time dependent current, which is indicative of

Q : ( C , T) = No [ logA ( ADC) ;]

o [ logA (ADC );]

the power of light detected , wherein the at least one or a ratio factor Y , (C , T) based on the analog -to -digital
photocurrent signal generating light detector includes a converter voltage output A (ADC ); of an ith analog - to - digital
preamplifier having a feedback resistor ; and
65 converter and an analog -to -digital converter voltage output
a light absorbance change determining algorithm imple- A ( ADC ); of a jth analog- to -digital converter, where a is a
mented processor programmed to calculate a change in standard deviation according to the equation :
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logA ( ADC );]
Y ;; ( C , T) = oo [[logA
( ADC);

wherein T is a temperature of the biological sample and C
is a concentration of blood glucose in the biological sample .

5

